Trelegy Ellipta vs Skyrizi
Side-by-side drug price comparison from Medicare Part D data
Verdict
Trelegy Ellipta costs 92% less per claim than Skyrizi ($380.00 vs $4475.00). Neither drug has a generic alternative available. Total Medicare spending: Trelegy Ellipta at $2.9B vs Skyrizi at $2.3B.
| Metric | Trelegy Ellipta | Skyrizi |
|---|---|---|
| Avg Cost per Claim Average cost Medicare pays per prescription claim | $380* | $4,475 |
| Total Medicare Spending Total Medicare Part D spending on this drug | $2.9B | $2.3B |
| Total Claims | 7,560,000 | 524,000 |
| Year-over-Year Change Price change from prior year (lower is better for patients) | 19.8%* | 42.8% |
| Generic Available | No | No |
| Condition | Asthma/COPD | Autoimmune Diseases |
| Total Beneficiaries | 865,000 | 78,000 |
Trelegy Ellipta costs 92% less per claim than Skyrizi ($380.00 vs $4475.00). Neither drug has a generic alternative available. Total Medicare spending: Trelegy Ellipta at $2.9B vs Skyrizi at $2.3B.
Explore More
The side-by-side above pulls the CMS Medicare Part D Drug Spending data data for both Trelegy Ellipta and Skyrizi. What follows is the interpretation — which specific axes carry the most weight for Trelegy Ellipta versus Skyrizi, and which differences are large enough to influence a real decision.
For households or analysts using this comparison as a decision input, the right framing is usually not "which is better" in aggregate but "which is better for the specific decision in front of you." CMS Medicare Part D Drug Spending data captures the raw data; the framing depends on whether the question is investment, residency, planning, or research.
Source: CMS Medicare Part D Spending, 2026.